This is a multicenter, single-arm, open-label, investigator-initiated, phase II clinical trial designed to evaluate the feasibility, efficacy, and safety of Mosunetuzumab in combination with Tislelizumab in patients with relapsed/refractory follicular lymphoma (r/r FL).
Signed written informed consent.
Age ≥18 years.
Histologically confirmed relapsed/refractory follicular lymphoma (r/r FL).
Received at least two prior systemic therapies, including anti-CD20 monoclonal antibody therapy.
Inability to comply with study hospitalization and restrictions.
Active infections (including tuberculosis) or immunocompromised status.
Prior history of severe hypersensitivity to similar agents.
CNS involvement of lymphoma.